Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer by Miles, David et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole
limpet hemocyanin (KLH) vaccine for metastatic breast cancer
Citation for published version:
Miles, D, Roché, H, Martin, M, Perren, TJ, Cameron, DA, Glaspy, J, Dodwell, D, Parker, J, Mayordomo, J,
Tres, A, Murray, JL, Ibrahim, NK & Theratope® Study Group 2011, 'Phase III multicenter clinical trial of the
sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer' The Oncologist, vol.
16, no. 8, pp. 1092-100. DOI: 10.1634/theoncologist.2010-0307
Digital Object Identifier (DOI):
10.1634/theoncologist.2010-0307
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
The Oncologist
Publisher Rights Statement:
The Oncologist 2011. Europepmc open access option
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole
Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
DAVID MILES,a HENRI ROCHÉ,b MIGUEL MARTIN,c TIMOTHY J. PERREN,d DAVID A. CAMERON,e
JOHN GLASPY,f DAVID DODWELL,g JOANNE PARKER,h JOSÉ MAYORDOMO,i ALEJANDRO TRES,i
JAMES LEE MURRAY,j NUHAD K. IBRAHIM, AND THE THERATOPE STUDY GROUP
aMount Vernon Cancer Center, Northwood, Middlesex, United Kingdom; bMedical Oncology, Institut
Claudius Regaud, Toulouse, France; cOncology Service, Hospital Clinico San Carlos, Madrid, Spain;
dCRUK Cancer Medical Research, St. James University Hospital, Leeds, United Kingdom; eMedical
Oncology, Western General Hospital, Edinburgh, Scotland, United Kingdom; fMedical/Surgical Oncology,
University of California Los Angeles School of Medicine, Los Angeles, California, USA; gClinical Oncology,
Cookridge Hospital, Hospital Lane, West Yorks, Leeds, United Kingdom; hResearch and Development,
Biomira, Inc., Edmonton, Alberta, Canada; iServicio de Oncologia Medica, Hospital Clinico Universitario
Lozano Blesa, Zaragoza, Spain; jBreast Medical Oncology, University of Texas MD Anderson Cancer Center,
Houston, Texas, USA
Key Words. Metastatic breast cancer • MUC-1 antibody • Antiestrogen • Vaccine • Chemotherapy
Disclosures: David Miles: None; Henri Roché: None; Miguel Martin: None; Timothy J. Perren: None; David A. Cameron:
None; John Glaspy: None; David Dodwell: None; Joanne Parker: None; José Mayordomo: None; Alejandro Tres: None;
James Lee Murray: None; Nuhad K. Ibrahim: None.
The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from
commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent
peer reviewers.
ABSTRACT
Purpose. This double-blind, randomized, phase III clin-
ical trial evaluated time to progression (TTP) and over-
all survival in women with metastatic breast cancer
(MBC) who received sialyl-TN (STn) keyhole limpet he-
mocyanin (KLH) vaccine. Secondary endpoints in-
cluded vaccine safety and immune response.
Experimental design. The study population consisted
of 1,028 women with MBC across 126 centers who had
previously received chemotherapy and had had either a
complete or a partial response or no disease progres-
sion. All women received one-time i.v. cyclophospha-
mide (300 mg/m2) 3 days before s.c. injection of 100 g
STn-KLH plus adjuvant (treatment group) or 100 g
KLH plus adjuvant (control group) at weeks 0, 2, 5, and
9. Subsequently, STn-KLH without adjuvant or KLH
without adjuvant was then administered monthly for 4
months, and then quarterly until disease progression,
without cyclophosphamide.
Results. STn-KLH vaccine was well tolerated; pa-
tients had mild to moderate injection-site reactions and
reversible flu-like symptoms. Week-12 antibody testing
revealed high specific IgG titers and a high rate of IgM-
to-IgG seroconversion; the median IgG titers in STn-
KLH recipients were 320 (anti-ovine submaxillary
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mucin) and 20,480 (anti-STn), with no detectable an-
timucin antibodies in the control group. The TTP was
3.4 months in the treatment group and 3.0 months in the
control group. The median survival times were 23.1
months and 22.3 months, respectively.
Conclusions. Although STn-KLH was well toler-
ated in this largest to date metastatic breast cancer
vaccine trial, no overall benefit in TTP or survival
was observed. Lessons were learned for future vac-
cine study designs. The Oncologist 2011;16:1092–1100
INTRODUCTION
Breast cancer is the most common type of cancer in women,
with 1.05 million new cases diagnosed annually [1]. It was
estimated that, in 2009, in the U.S., 192,370 women would
be diagnosed with breast cancer and 40,170 women would
die as a result of this disease; in Europe, the corresponding
estimates for 2006 were 429,900 women diagnosed and
131,900 deaths [2, 3]. The 5-year survival rate for women
with distant metastasis from breast cancer is only 26% in
the U.S. and20% in Europe [2, 4].
Therapeutic cancer vaccines are increasingly being
studied in the treatment of breast cancer; they may induce
relevant humoral and/or cell-mediated immunity to tumor
cells. These cancer vaccines can consist of whole tumor
cells/lysates or defined tumor antigens [5, 6]. One poten-
tially important tumor-associated antigen is sialyl-Tn
(STn), a carbohydrate epitope found on a variety of glyco-
proteins, including cancer-associated mucins [7, 8]. STn
expression is associated with a poor prognosis in metastatic
colorectal, gastric, ovarian, and breast cancer patients [9–
13]. A synthetic STn antigen was generated for use as a
therapeutic cancer vaccine antigen, and tests in animal
models and human studies showed the antigen to be safe
and to produce a strong immune response [8, 14–17]. STn-
keyhole limpet hemocyanin (KLH) (Theratope; Biomira,
Inc., Edmonton, Canada), a synthetic STn conjugated to the
KLH carrier protein, has been used in conjunction with
Enhanzyn™ (previously called Detox B stable emulsion;
Corixa Corp., Hamilton, MA) adjuvant therapy (hereafter
referred to as “adjuvant”) [15]. The immune response to ad-
ministered antigens may be augmented using “immuno-
modulatory” doses of a variety of cytotoxic agents, such as
cyclophosphamide, which have been posited to exert their
effect by inhibiting putative suppressor T regulatory cells
(Treg) or by increasing the humoral response to STn-KLH
vaccine [17–19].
The efficacy of and clinical outcomes associated with
cyclophosphamide and STn-KLH treatment in patients
with metastatic breast cancer (MBC) have been measured
in several studies by examining patients’ antimucin anti-
bodies and T-cell responses and correlating these immune
responses with overall survival [8, 16, 20, 21]. In addition,
a phase II multicenter trial of STn-KLH plus adjuvant dem-
onstrated STn-KLH’s safety and immunogenicity [22]. The
primary goals of this phase III trial were to evaluate the ef-
fects of STn-KLH vaccine compared with a control vaccine
on TTP and overall survival in a large international cohort
of women with MBC. Secondary endpoints were vaccine
safety, serum antibody response, and self-reported quality
of life (QoL).
MATERIALS AND METHODS
Patient Eligibility, Randomization,
and Stratification
This double-blind, randomized study was conducted across
126 centers in 10 countries. The study was approved by the
independent ethics committee or institutional review board
at each site. Patients provided institutionally approved in-
formed consent before being enrolled in the study.
Eligible patients were aged18 years, had histological-
ly/cytologically proven breast cancer, and had either no ev-
idence of disease (NED) or no progressive disease (NPD)
following first-line chemotherapy for MBC. The chemo-
therapy had to have begun no later than 40 weeks and ended
no later than 3 weeks before study entry. Stable disease was
required for at least 24 weeks for study entry. Patients were
also required to have a neutrophil count 1.0  109/L, a
platelet count 75  109/L, a hemoglobin level 9 g/dL,
and an Eastern Cooperative Oncology Group performance
status score 2. Women with bone metastases as the only
metastatic site of disease were eligible for inclusion in the
trial.
In total, 1,030 women were enrolled in the trial but two
patients experienced progression of disease prior to initia-
tion of treatment and were excluded; therefore, 1,028 pa-
tients were randomized to either the STn-KLH (test) or
KLH (control) groups following evaluation, receipt of in-
formed consent, and determination of eligibility. The inves-
tigators and patients were blinded to test versus control
therapy assignments.
Additionally, patients were stratified as NED or NPD
according to their disease status following first-line chemo-
therapy. As a result of slow study accrual, a protocol
amendment was implemented that allowed the inclusion of
women receiving concomitant hormone therapy to treat
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their MBC. All but the first 150 patients were enrolled in the
study under this amended protocol. To ensure the statistical
integrity of the study, two additional strata were added prior
to patient randomization: no hormone therapy or concomi-
tant anticancer hormone therapy.
Vaccine Formulation and Clinical
Treatment Protocol
Preclinical studies demonstrated that a higher conjugation
ratio of STn to KLH led to greater specific antibody titers
(internal Biomira results). An optimized formulation of
STn-KLH was therefore developed in an attempt to in-
crease the immune response in patients. Prior to the phase
III trial, the week-12 antibody response to the optimized
vaccine formulation was studied in a phase II trial of 36
MBC patients, confirming the immunogenicity of the new
formulation (BR-103 bridging study; data not published).
The new formulation is chemically identical to that used in
the early phase I/II studies, but has a greater conjugation ra-
tio of STn to KLH of approximately 9%, compared with
the conjugation ratio of approximately 5% found in the
STn-KLH vaccine used in previous phase I/II studies
[15–17, 23].
Patients were evaluated for study eligibility within 14
days prior to receiving a single i.v. dose of 300 mg/m2 cy-
clophosphamide. Three days following this pretreatment,
patients in the KLH group (n 505) received 100 g KLH
and patients in the STn-KLH group (n 523) received 100
g STn-KLH administered s.c. Treatments were given on
weeks 0, 2, 5, 9, 13, 17, 21, 25, and 37, and every 12 weeks
thereafter. Patients were evaluated for disease status, both
clinically and radiologically, by repeat studies on weeks 12,
24, 36, 48, and 60, or as clinically indicated.
For the initial treatment period (weeks 0, 2, 5, and 9),
both STn-KLH and KLH were admixed with adjuvant for
s.c. injection (with a half dose delivered to each of two body
sites: a deltoid muscle of the upper arm and/or the antero-
lateral region of the upper thigh). The adjuvant was with-
drawn in the event of a significantly higher rate of
ulceration at the injection sites or ulceration not ameliorated
by withholding the adjuvant [15]. The adjuvant was omitted
after week 12 to ameliorate potential ulceration at injection
sites; thus, vaccine without adjuvant was administered to
patients continuing in the subsequent treatment period
(weeks 13, 17, 21, and 25, and every 3 months thereafter).
Primary safety, tumor, and immune response evaluations
were done at week 12; however, data on the sustainability
of the antibody response beyond week 12 were not avail-
able. Patients were withdrawn from the trial at the first signs
of disease progression, as determined by the investigator.
Patients were also withdrawn from the study at the discre-
tion of the investigator or at the request of the patient.
Measurement of Primary Endpoints
TTP was defined as the time between the first vaccination
and disease progression, patient death, or last patient con-
tact. Overall survival was defined as the time between the
first vaccination and patient death or last patient contact. To
determine disease progression, patient radiologic images
were reviewed by radiologists on the Response Evaluation
Committee, who remained blind to treatment assignments.
World Health Organization criteria were used to define dis-
ease progression: an increase 25% in the product of the
two largest perpendicular diameters of a bidimensionally
measurable lesion; a 25% increase in a single diameter of a
unidimensionally measurable lesion; or the appearance of a
new lesion upon clinical examination or imaging scan, in-
cluding computed tomography radiograph, ultrasonogra-
phy, or plain film radiograph of the bone. A conservative
approach was taken for the statistical analysis of disease
progression by using the earliest date of progression as de-
termined by the investigator or the Response Evaluation
Committee. Disease response was not examined.
Measurement of Secondary Endpoints
The investigators were blinded to the treatment assign-
ments and the safety, QoL, and immunologic testing re-
sults. Safety evaluations were conducted by the clinical
research team at each site during each vaccination visit.
These evaluations consisted of physical examinations (in-
cluding injection site inspections), standard clinical labora-
tory tests, and reports of adverse events (AEs). In addition,
a data safety monitoring board analyzed the safety evalua-
tions and ensured the statistical robustness of the sample
size estimates following enrollment of 300, 600, 800, and
1,000 patients and during the TTP, interim survival, and fi-
nal survival analyses.
QoL data were collected at baseline (day of first cyclo-
phosphamide injection), week 12, and then every 3 months us-
ing the 30-item European Organization for Research and
Treatment of Cancer QLQ C30 [24] cancer survey and a 23-
item breast cancer-specific module [24]. QoL data gathering
was discontinued upon disease progression or patient death.
To determine the patients’ immune response, serum ti-
ters of antiovine submaxillary mucin (anti-OSM), which
contains both clustered and unclustered forms of the STn
epitope and is believed to be representative of native STn
present on tumor-associated mucin [25], in addition to anti-
STn and anti-KLH IgM and IgG antibodies were measured
at week 12 using an enzyme-linked immunosorbent assay
as previously described [13].
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Statistical Analyses
Event-based TTP and interim survival analyses were per-
formed in September 2002, with a final survival analysis in
June 2003. The primary TTP analysis occurred following
800 progression events (achieving 87% power to observe a
30% longer TTP), and the interim survival analysis oc-
curred following 488 patient deaths (achieving 67%
power). The final survival analysis occurred after at least
650 deaths (to allow an 89% power to observe a 30% longer
overall survival time). The  level was adjusted based on
the actual number of events at the time of analysis. The
Lan–DeMets [26] implementation of the O’Brien–Fleming
[27] method of calculating an adjusted  level was used.
The p-values adopted were.0145 and.0357 for the in-
terim and final analyses, respectively.
For both the TTP and survival time, the differences
between the STn-KLH and KLH groups were evaluated
following an initial analysis using the Cox proportional
hazards regression model; a secondary analysis was per-
formed using an overall log-rank test. The Cox model
was conducted using the stratification variables as fac-
tors and adjusting for a specific prognostic variable (time
from initial diagnosis to first metastasis). The protocol
assumptions were that 20% of patients would be catego-
rized in the NED group and 80% would be categorized in
the NPD group.
An overall p  .05 was considered statistically signifi-
cant. This was achieved using a significance level of .01 for
the TTP differences and a significance level of .04 for the
survival differences between treatment groups.
Descriptive statistics were used for injection site reac-
tions, AEs, QoL, and antimucin or anti-KLH antibody
titers. Patients were considered evaluable for the immu-
nologic endpoints if they provided a blood sample follow-
ing the first four vaccinations (week 12). Treatment effect
analyses were also performed by treatment group using the
slope of the QoL curve score over time (time-adjusted area
under the change-from-baseline curve).
RESULTS
Clinical Study and Patient Characteristics
This phase III trial was the largest ever randomized, dou-
ble-blind vaccine study in women with MBC. The trial
began enrollment in November 1998 and the final anal-
ysis of all endpoints concluded in June 2003, with fol-
low-up of surviving patients ongoing at the time of this
writing. One thousand twenty-eight patients were ran-
domized to the study. Data were missing for six patients.
Therefore, 1,022 patients were evaluable for TTP and
survival time analyses (Fig. 1). However, during the
course of the study, 34 patients were taken off the proto-
col because of AEs or withdrawal of consent. The data
from these patients were considered censored at the time
of withdrawal.
Table 1 summarizes the patient demographic and base-
line disease characteristics. There were no significant dif-
ferences between the STn-KLH and KLH groups. The
patients’ median age at diagnosis of their primary cancer
was 53 years.
There were no significant differences in disease charac-
teristics between the treatment groups. The most common
sites of metastasis included the bone (61%), liver (42%),
and lungs (34%). Most of the patients in both the STn-KLH
(75.7%) and KLH (78.6%) groups had visceral disease
(supplemental online Table A).
 
Enrolled 
n = 1030 
Randomized 
n = 1028 
Treatment 
n = 523 
Control  
n = 505 
Subjects evaluable  
for TTP and survival 
n = 521 
Subjects evaluable  
for TTP and survival 
n = 501 
Withdrew consent  
n = 10 
Withdrew due to 
adverse event 
n = 5 
Withdrew due to 
adverse event 
n = 7
Withdrew consent  
n = 12 
Figure 1. CONSORT diagram.
Abbreviation: TTP, time to progression.
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Prior to study entry, most participants (90%) had
NPD (56% had a partial response, 23% had stable dis-
ease, and 11% had a minor response), whereas 10% had
NED following first-line chemotherapy. Following the
protocol amendment, 31% of the patients received hor-
mone therapy in addition to the study medication; these
patients were stratified equally between the treatment
groups.
PRIMARY ENDPOINTS: TTP AND
OVERALL SURVIVAL
There were no significant differences in the median TTP or
overall survival time between the treatment groups. The
median TTP was 3.4 months for the STn-KLH group and
3.0 months for the KLH group (Cox proportional hazards
model p .353; log-rank test p .305) (Fig. 2).
At the final analysis, the median overall survival times
of the patients in the STn-KLH and KLH groups were 23.1
months and 22.3 months, respectively (Cox p  .916). A
secondary analysis of survival duration using log-rank sta-
tistics revealed a similar lack of a significant difference
(p .972) (Fig. 3). Likewise, there were no significant dif-
ferences in TTP or overall survival time according to dis-
ease status (NED or NPD) or hormone therapy use.
Secondary Endpoints: Safety and AEs, QoL, and
Antibody Response
In the STn-KLH group, 2,482 AEs were reported in 464
(89%) patients, and in the KLH group, 2,255 AEs were re-
ported in 441 (87%) patients. Five patients (1%) in the STn-
KLH group and seven patients (1.4%) in the KLH group
withdrew as a result of AEs (supplemental online Table B).
There were 298 and 278 AEs (mostly grade 1 or 2 nausea
and/or vomiting) ascribed to cyclophosphamide prior to the
first injection of STn-KLH and KLH, respectively.
Following the first four vaccinations, injection site re-
actions, including burning/stinging, erythema, pain, itch-
ing, and indurations, were common. Ulcerations at the
injection site were seen in 91 (9%) and 61 (12%) patients in
the STn-KLH and KLH groups, respectively (supplemental
online Table C). Following discontinuation of the adjuvant
in affected patients, the incidence of ulcerations dropped to
1.5%.
The vaccine was well tolerated, with only 233 patients
experiencing one or more serious events—117 patients in
the STn-KLH group and 116 patients in the KLH group
(Table 2).
The most common AEs are shown in supplemental on-
line Table D. Patient-reported QoL was not significantly
different between the STn-KLH and KLH groups (data not
shown).
Week-12 median titers of antimucin and anti-KLH an-
tibodies better illustrate the specificity of the humoral im-
mune responses in the two treatment groups (Table 3 and
supplemental online Table E). Patients in the STn-KLH
group developed high titers of IgM and IgG antibodies to
OSM. The median survival duration for the 367 STn-KLH
patients with an antibody determination followed a dose re-
sponse–like outcome: an OSM IgG response less than the
Table 1. Patient demographic and baseline disease
characteristics by treatment group
Characteristic n of patients (%)
STn-KLH
(n 521)
KLH
(n 501)
Total
(n 1,022)
Median age, yrs 53 53 53
Estrogen receptor
expression
Positive 300 (57) 284 (57) 584 (57)
Negative 145 (28) 142 (28) 287 (28)
Not available 76 (15) 75 (15) 151 (15)
Progesterone receptor
expression
Positive 226 (43) 206 (41) 432 (42)
Negative 161 (31) 164 (33) 325 (32)
Not available 134 (26) 131 (26) 265 (26)
HER-2 overexpression
Yes 83 (16) 74 (14) 157 (15)
No 166 (32) 137 (27) 303 (30)
Unknown 272 (52) 288 (57) 560 (55)
Time from primary
diagnosis to first
metastasis, mos
n of patients 521 501 1022
Median 34.8 35.5 35.3
25th, 75th percentile 13.1, 63.6 15.2, 67.6 13.8, 67.0
Time from first
metastasis to first
injection of
vaccine, mos
n of patients 521 501 1022
Median 7.9 8.0 8.0
25th, 75th percentiles 6.3, 12.1 6.1, 13.0 6.2, 12.7
Category of diseasea 396 (75.7) 397 (78.6) 793 (77.1)
Visceral 58 (11.1) 46 (9.1) 104 (10.1)
Superficial 67 (12.8) 58 (11.5) 125 (12.2)
Bone only
aVisceral disease any central nervous system, liver,
lung, mediastinum, kidney, or pleura disease, ascites, or
pleural effusion; superficial disease any metastasis to
the lymph nodes, skin, soft tissue, left breast, right breast,
or chest wall, but no visceral or bone metastases; bone
only metastatic disease limited to the bone.
Abbreviations: HER-2, human epidermal growth factor
receptor; KLH, keyhole limpet hemocyanin; STn,
sialyl-TN.
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median, 24 months; equal to the median, 28.4 months; and
greater than the median, 31.9 months (Cox p .1794).
DISCUSSION
Herein, we report the results of the largest and, to our
knowledge, the only double-blind, randomized, multicenter
phase III trial of a candidate therapeutic cancer vaccine in
patients with MBC. Although the primary endpoints were
not met, many clinical and immunological lessons were
learned.
The therapeutic cancer vaccine—STn-KLH— did not
appear to be detrimental to the intent-to-treat population,
but neither did it provide a survival benefit or longer TTP,
despite a vigorous and specific humoral response to the
STn antigen. To our knowledge, no results have been
published regarding survival following a therapeutic
cancer vaccine in patients with MBC previously treated
with chemotherapy.
The development of a specific anticancer–antigen hu-
moral immune response is thought to be important in fight-
Figure 2. Kaplan–Meier curves of time to disease progression (combined assessment).
Abbreviations: KLH, keyhole limpet hemocyanin; STn, sialyl-TN.
Figure 3. Kaplan–Meier curves of survival duration.
Abbreviations: KLH, keyhole limpet hemocyanin; STn, sialyl-TN.
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ing metastatic cancer [28 –30]. In this trial, STn-KLH
vaccine led to high levels of anti-OSM and anti-STn anti-
bodies and seroconversion from IgM to IgG; however, pa-
tients who received KLH did not have significant antimucin
responses. Anti-KLH antibody responses were present in
both groups, but at lower median levels in the STn-KLH
group. This is to be expected, because one would predict a
higher response to the hapten (STn) than to the carrier
(KLH) in an appropriately designed vaccine. Despite a suc-
cessful antibody response to STn-KLH, there was no evi-
dence that STn-KLH had a significant effect on the primary
endpoints. Perhaps the tumor-specific antibody response to
STn did not occur in time to prevent disease progression,
particularly because the patients in this study had advanced
metastatic disease, or perhaps its clinical benefit was
blurred by a nontumor-specific immune response against
KLH in the control arm. In other words, if a placebo arm
was used instead of the KLH control arm, a significantly
longer TTP could not be ruled out.
The design of this study was such that all patients
stopped treatment upon disease progression or toxicity; we
cannot therefore exclude the possibility that continued vac-
cination beyond primary progression might have been ad-
vantageous. An STn-KLH vaccine trial in women with
early-stage breast cancer, in whom the tumor burden is
smaller, may better address this issue.
Future designs with antimucin antibodies should verify
the potential clinical interaction between mucin (MUC)-1
and antiestrogen regulatory pathways, as the clinical out-
come of this study hinted to. Supported by preclinical stud-
ies that detailed the modulation by and interaction of
MUC-1 with estrogen receptors and various other relevant
gene pathways [31, 32], we may, therefore, justify prospec-
tive clinical studies to address this issue. Furthermore,
patients in this study received only one dose of cyclophos-
phamide infusion as a Treg suppressor [33, 34]. It was pre-
viously demonstrated that patients who received low-dose
cyclophosphamide infusion versus no cyclophosphamide
achieved significantly higher IgG and IgM titers to STN-
KLH after four treatments (weeks 0, 2, 5, and 9) and a lower
rate of disease progression at week 9 [16, 17]. It is not clear
from this study whether the clinical benefit was a direct ef-
fect of cyclophosphamide infusion, although all published
data imply that the dose of cyclophosphamide used (300
mg/m2) is of no substantial clinical effect. Whether the Treg
suppressive effect of cyclophosphamide resulted in enhanc-
ing the immunological antitumor response—and therefore,
maintaining the use of this immune-suppressive dose of cy-
clophosphamide would have brought a better clinical out-
come—remains to be seen.
Consistent with all other previous trials of STn-KLH,
we also found that STn-KLH had an acceptable safety pro-
file [19, 21]. Patient tolerance of both STn-KLH and KLH
was very good, with similar QoL data in both treatment
arms.
The optimal method for detecting carbohydrate epitopes
is unclear, and as a consequence, estimates of the expres-
sion of STn in breast tumors have varied considerably
(16%–91%). Although patient selection based on the level
of STn expression in the tumor seems prudent, the lack of
an established method for determining STn expression at
the time of the study design led to the decision to enroll pa-
tients without attempting to phenotype tumors. Future trials
with targeted therapies may benefit from this acknowl-
edged limitation of our study, and restrict patient enroll-
ment to those who express the target in question.
The main concern in evaluating the relationship be-
tween an immune response and antitumor activity was the
possibility of ascribing a causal relationship to what might
simply have been a casual relationship—for example, some
patients may have been more capable of generating a higher
immune response or may have had a smaller tumor burden,
or perhaps an unknown molecular pathway associated with
a more favorable outcome in terms of progression-free and
overall survival may have been present. Perhaps testing
for antibody responses over time and correlating these re-
sponses with the trial endpoints could have addressed
this unknown. This exercise may have been particularly
enlightening if tumor blocks had been available for post
Table 2. AEs in randomized patients
n of patients (%)
STn-KLH
(n 521)
KLH
(n 501)
Total
(n 1,022)
n of AEs 2,482 2,255 4,737
Patients with AEs 464 (89) 441 (87) 905 (88)
Patients who withdrew
because of AEs
5 (1.0) 7 (1) 12 (1)
Patients with serious
AEs
117 (22) 116 (23) 233 (23)
Patients with AEs by
toxicity gradea
Grade 1 127 (27) 111 (25) 238 (26)
Grade 2 194 (42) 188 (43) 382 (42)
Grade 3 90 (19) 85 (19) 175 (19)
Grade 4 19 (4) 15 (3) 34 (4)
Grade 5 34 (7) 42 (10) 76 (8)
aIf a patient experienced more than one adverse event, the
patient was counted only once at the worst grade.
Abbreviations: AE, adverse event; KLH, keyhole limpet
hemocyanin; STn, sialyl-TN.
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hoc STn expression testing, which was not the case for
our study.
Although modest improvements in TTP and survival
have been noted as a consequence of novel chemotherapeu-
tic combinations or the addition of biologic therapies, MBC
remains largely incurable [35]. Novel therapeutic strategies
are clearly required. Despite the disappointing results of
this randomized, controlled phase III trial, there continues
to be a place for better-designed and targeted therapeutic
cancer vaccine trials. Patients should be selected based on
the targeted antigen, and the vaccine should be adminis-
tered alone or in conjunction with standard treatments, en-
gaging the immune systems of cancer patients to improve
clinical outcomes. This study confirmed the safety, tolera-
bility, and humoral immune–stimulating capabilities of
STn-KLH in a large international group of women with
MBC. Although promising in preclinical and phase II trials,
STn-KLH vaccine did not show any overall efficacy in this
larger and randomized study. Selection of patients with
minimal tumor burden and indolent disease (e.g., those with
estrogen receptor–positive tumors) and a longer duration of
vaccination with continued Treg suppression should be ex-
plored in future designs.
SUMMARY
Despite the knowledge of many cancer-related antigens and
the potential development of therapeutic vaccines, this has
not yet been translated into clinical use. This is the first ran-
domized trial using an anti–MUC-1 vaccine in the manage-
ment of MBC. Although it did not meet its primary
objectives, we did show that it can be safely administered.
Subsequent preclinical research suggests modulation of
the estrogen receptor by MUC-1 and a resultant down-
stream signaling effect on cell proliferation. Although anti-
estrogen was given in combination with the vaccine in a
subset of patients, a subset analysis was not planned or
powered to address this modulation effect.
Our report may represent a true incentive for additional
translational research to explore the potential benefit of
combining an antiestrogen with a MUC-1 vaccine to vali-
date the preclinical data, supported by the safety of this ap-
proach as shown in this manuscript.
ACKNOWLEDGMENTS
The authors would like to acknowledge the MD Anderson
Department of Scientific Publications for editorial support,
Cynthia Griffin for secretarial assistance, and all patients in
the trial.
Funding for conducting this study, data analysis, and re-
porting was provided by Biomira, Inc., Edmonton, AB,
Canada; Chiron Corporation, Emeryville, CA, USA, and
Merck KGaA, Darmstadt, Germany.
N. K. Ibrahim had full access to all the data in the study
and had final responsibility for the decision to submit for
publication.
Joanne Parker is currently at IBT Laboratories, Lenexa,
Kansas.
AUTHOR CONTRIBUTIONS
Conception/Design: Nuhad K. Ibrahim, David Miles, Joanne Parker, James
L. Murray
Administrative support: Nuhad K. Ibrahim, David Miles, Joanne Parker
Provision of study material or patients: Nuhad K. Ibrahim, David Miles,
Henri Roché, Miguel Martin, Timothy J. Perren, David A. Cameron,
John Glaspy, David Dodwell, José Mayordomo, Alejandro Tres, James L.
Murray
Collection and/or assembly of data: Nuhad K. Ibrahim, David Miles
Data analysis and interpretation: Nuhad K. Ibrahim, David Miles
Manuscript writing: Nuhad K. Ibrahim, David Miles
Final approval of manuscript: Nuhad K. Ibrahim
The authors take full responsibility for the content of the paper but thank Dr.
Sheela Hota-Mitchell (Write On Science) and Dory Smith (Biomera) for assis-
tance with the manuscript.
REFERENCES
1 Parkins DM. International variation. Oncogene 2004;23:6329–6340.
2 American Cancer Society. Cancer Facts and Figures 2005. Atlanta, GA:
American Cancer Society, Inc., 2005;1–60.
3 Ferlay J, Autier P, Boniol M et al. Estimates of cancer incidence and mor-
tality in Europe in 2006. Ann Oncol 2007;18:581–592.
4 Sant M, Allemani C, Berrino F et al. Breast carcinoma survival in Europe
and the United States. Cancer 2004;100:715–722.
5 Jäger E, Jäger D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immu-
nol 2002;14:178–182.
6 Bitton RJ. Cancer vaccines: A critical review on clinical impact. Curr Opin
Mol Ther 2004;6:17–26.
7 Musselli C, Livingston PO, Ragupathi G. Keyhole limpet hemocyanin con-
jugate vaccines against cancer: The Memorial Sloan Kettering experience.
J Cancer Res Clin Oncol 2001;127(suppl 2):R20–R26.
8 Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-
Table 3. Median antibody titers at week 12
Treatment Anti-OSM IgM Anti-OSM IgG Anti-STn IgM Anti-STn IgG Anti-KLH IgM Anti-KLH IgG
STn-KLH 1,280 320 10,240 20,480 80 20,480
KLH 0 0 0 0 1,280 81,920
Abbreviations: KLH, keyhole limpet hemocyanin; OSM, ovine submaxillary mucin; STn, sialyl-TN.
1099Miles, Roché, Martin et al.
www.TheOncologist.com
KLH) as treatment for breast cancer. Expert Rev Vaccines 2004;3:655–
663.
9 Miles DW, Happerfield LC, Smith P et al. Expression of sialyl-Tn predicts
the effect of adjuvant chemotherapy in node-positive breast cancer. Br J
Cancer 1994;70:1272–1275.
10 Miles DW, Linehan J, Smith P et al. Expression of sialyl-Tn in gastric can-
cer: Correlation with known prognostic factors. Br J Cancer 1995;71:
1074–1076.
11 Kinney AY, Sahin A, Vernon SW et al. The prognostic significance of sia-
lyl-Tn antigen in women treated with breast carcinoma treated with adju-
vant chemotherapy. Cancer 1997;80:2240–2249.
12 Kolbayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent
predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin
Oncol 1992;10:95–101.
13 Longenecker BM, Reddish M, Koganty R et al. Immune responses of mice
and human breast cancer patients following immunization with synthetic
sialyl-Tn conjugated to KLH plus detox adjuvant. Ann N Y Acad Sci 1993;
690:276–291.
14 Itzkowitz SH, Yuan M, Montgomery CK et al. Expression of Tn, sialosyl-
Tn, and T antigens in human colon cancer. Cancer Res 1989;49:197–204.
15 MacLean GD, Reddish M, Koganty RR et al. Immunization of breast can-
cer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant.
Cancer Immunol Immunother 1993;36:215–222.
16 MacLean GD, Reddish MA, Koganty RR et al. Antibodies against mucin-
associated sialyl-Tn epitopes correlate with survival of metastatic adeno-
carcinoma patients undergoing active specific immunotherapy with
synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996;19:
59–68.
17 Miles DW, Towlson KE, Graham R et al. A randomised phase II study of
sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pre-
treatment for the active specific immunotherapy of breast cancer. Br J Can-
cer 1996;74:1292–1296.
18 Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophos-
phamide in the active specific immunotherapy of cancer. Cancer Immunol
Immunother 1998;47:1–12.
19 MacLean GD, Miles DW, Rubens RD et al. Enhancing the effect of THER-
ATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer
by pretreatment with low-dose intravenous cyclophosphamide. J Immu-
nother Emphasis Tumor Immunol 1996;19:309–316.
20 Holmberg LA, Sandmaier BM. Theratope vaccine (STn-KLH). Expert
Opin Biol Ther 2001;1:881–891.
21 Reddish MA, MacLean GD, Poppema S et al. Pre-immunotherapy serum
CA27.29 (MUC-1) mucin level and CD69 lymphocytes correlate with ef-
fects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immu-
notherapy. Cancer Immunol Immunother 1996;42:303–309.
22 Vogel C, Sandmaier BM, Burris H et al. Theratope (STn-KLH) with
Detox™-B stable emulsion for treatment of MBC following first-line che-
motherapy. Presented at the 1999 Annual Meeting of the American Society
of Clinical Oncology, Atlanta, Georgia, May 15–18, 1999.
23 Miles D, Papazisis K. Rationale for the clinical development of STn-KLH
(Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer
2003;3(suppl 4):S134–S138.
24 Fayers P, Aaronson N, Bjordal K et al. EORTC QLQ-C30 Scoring Manual.
Brussels, Belgium: EORTC Study Group on Quality of Life, 1995.
25 Zhang S, Walberg LA, Ogata S et al. Immune sera and monoclonal anti-
bodies define two configurations for the sialyl Tn tumor antigen. Cancer
Res 1995;55:3364–3368.
26 Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Bi-
ometrika 1983;70:654–663.
27 O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials.
Biometrics 1979;35:549–556.
28 Foy TM, Fanger GR, Hand S et al. Designing HER2 vaccines. Semin Oncol
2002;29(suppl 11):53–61.
29 Cristofanilli M, Hortobagyi GN. New horizons in treating metastatic dis-
ease. Clin Breast Cancer 2001;1:276–287.
30 Reilly RT, Emens LA, Jaffee EM. Humoral and cellular immune responses:
Independent forces or collaborators in the fight against cancer? Curr Opin
Investing Drugs 2001;2:133–135.
31 Pitroda SP, Khodarev NN, Beckett MA et al. MUC1-induced alterations in
a lipid metabolic gene network predict response of human breast cancers to
tamoxifen treatment. Proc Natl Acad Sci U S A 2009;106:5837–5841.
32 Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen
receptor alpha. Mol Cell 2006;21:295–305.
33 Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the im-
mune system of cancer patients: Depletion of CD4, 2H4 suppressor in-
ducer T-cell. Cancer Res 1988;48:1671–1675.
34 Berd D, Mastrangelo MJ, Engstrom PF et al. Augmentation of the human
immune response by cyclophosphamide. Cancer Res 1982;42:4862–4866.
35 Sànchez-Muñoz A, Pérez-Ruiz E, Ribelles N et al. Maintenance treatment
in metastatic breast cancer. Expert Rev Anticancer Ther 2008;
8:1907–1912.
1100 Phase III Trial of STn-KLH in Breast Cancer
